Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioporto ASTHOXF 70 EV-to-EBIT is -6.10 as of Jul. 22, 2026. GuruFocus rates THOXF with a GF Score™ of 70/100 and a GF Value™ of $0.16. The stock has 4 warning signs investors should review. Among 104 Medical Diagnostics & Research companies, Bioporto AS ranks worse than 961537.5% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bioporto AS's Enterprise Value for the quarter that ended in Dec. 2025 was $135.16 Mil.
Bioporto AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioporto AS EV-to-EBIT Related Terms
Bioporto AS EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bioporto AS's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Bioporto AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bioporto AS's EV-to-EBIT falls into.
Bioporto AS's current Enterprise Value is $80.84 Mil.
Bioporto AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioporto AS (THOXF) has a EV-to-EBIT of -6.10 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bioporto AS and its competitors. According to the industry distribution chart, Bioporto AS ranks #999999 out of 104 companies in the Medical Diagnostics & Research industry.
Is Bioporto AS's EV-to-EBIT too high?
Bioporto AS's current EV-to-EBIT is -6.10. Based on the distribution chart, Bioporto AS ranks #999999 out of 104 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Bioporto AS has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #999999 out of 104 companies for EV-to-EBIT. This places Bioporto AS in the lower half of its industry. The industry median EV-to-EBIT is 22.81. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.81, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bioporto AS and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current EV-to-EBIT is -6.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (THOXF) has a current EV-to-EBIT of -6.10. The stock's GF Value™ is $0.16, compared to a current price of $0.15 — trading 6.9% below its estimated fair value. The current EV-to-EBIT is -6.10. Bioporto AS's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bioporto AS (THOXF), the current EV-to-EBIT is -6.10 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (THOXF) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of $0.15 is trading 6.9% below its estimated GF Value™ of $0.16.
Key valuation signals for THOXF:
EV-to-EBIT: -6.10
GF Value™: $0.16 vs. price of $0.15 (6.9% below fair value)
No single metric tells the full story. See the THOXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
70GF Score
Get the complete analysis for THOXF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
THOXF has been successfully added to your 
